Compare NDSN & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDSN | EXAS |
|---|---|---|
| Founded | 1935 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.0B |
| IPO Year | N/A | N/A |
| Metric | NDSN | EXAS |
|---|---|---|
| Price | $238.15 | $101.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $265.33 | $76.38 |
| AVG Volume (30 Days) | 302.3K | ★ 10.1M |
| Earning Date | 12-10-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.95 | N/A |
| Revenue | $2,784,349,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $6.21 | $19.40 |
| Revenue Next Year | $4.45 | $13.51 |
| P/E Ratio | $29.92 | ★ N/A |
| Revenue Growth | 4.49 | ★ 14.47 |
| 52 Week Low | $165.03 | $38.81 |
| 52 Week High | $259.13 | $101.87 |
| Indicator | NDSN | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 90.08 |
| Support Level | $233.14 | $101.10 |
| Resistance Level | $240.18 | $101.43 |
| Average True Range (ATR) | 4.35 | 2.43 |
| MACD | 0.61 | 0.97 |
| Stochastic Oscillator | 84.11 | 97.99 |
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.